Sensorion SA
PAR:ALSEN
Sensorion SA
PAR:ALSEN
Price:
0.65
EUR
-7.14%
Market Closed
Market Cap:
€334.7m
Relative Value
The Relative Value of one
ALSEN
stock under the Base Case scenario is
0.11
EUR.
Compared to the current market price of 0.65 EUR,
Sensorion SA
is
Overvalued by 83%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALSEN
Relative Value
Base Case
0.11
EUR
Overvaluation 83%
Multiples Across Competitors
ALSEN Competitors Multiples
Sensorion SA Competitors
Sensorion SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Sensorion SA
PAR:ALSEN
|
334.7m EUR | 0 | -12 | -9.5 | -9.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.4B USD | 6.4 | 92.8 | 15.3 | 21.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.4B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.9B USD | 6.1 | 21.2 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.2B USD | 9.9 | 30.2 | 22.7 | 23.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.8B USD | 5.5 | 17.5 | 12.9 | 14.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.1 | 34.5 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.6 | 34 | 36.8 | 37.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
